PlaqueTec has secured $8million in equity financing to advance its vision of opening a new frontier of precision medicine for millions of patients with coronary artery disease (CAD). The funding was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors. It will support PlaqueTec’s ongoing BIOPATTERN trial, to which 300 patients are being recruited for endotyping, meaning their disease will be classified into distinct subtypes based on molecular mechanisms. The trial will improve understanding of CAD pathobiology and how it varies between individuals. T…
